LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus

Phase 4TerminatedNCT00349986

Sanofi4 enrolled

Overview

The rationale of the study is to determine: * the first dose and the titration of basal insulin * the exact daily time administration of basal insulin in poorly controlled type II diabetic patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetes Mellitus, Type 2

Interventions

Insuline glargineDRUG

Eligibility

Sex: ALLMin age: 40 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 Diabetes Mellitus * Insufficient combined oral antidiabetic treatment (biguanide + sulfonylurea) * BMI \>25 kg/m2 , \<30 kg/m2 * HbA1c value \>7.0%, \<9.0% within one month Exclusion Criteria: * Type 1 Diabetes Mellitus * Known malignancy * Drug or alcohol abuse * Severe liver disease * Renal failure (se Creatinine \> 150 micro mol/l) The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Locations (1)

Sanofi-Aventis

Budapest, Hungary

Outcomes

Primary Outcomes

HgbA1c measurement

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.